Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
Status:
Completed
Trial end date:
2020-10-05
Target enrollment:
Participant gender:
Summary
The study is designed as a three arm randomized Phase III, multicenter trial comparing two
calcineurin inhibitor (CNI)-free strategies for Graft-versus-Host Disease (GVHD) prophylaxis
to standard tacrolimus and methotrexate (Tac/Mtx) in patients with hematologic malignancies
undergoing myeloablative conditioning hematopoietic stem cell transplantation.
Phase:
Phase 3
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Collaborators:
Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI)